antipyrine has been researched along with Acute Confusional Senile Dementia in 10 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone treatment significantly elevated cell viability, reduced apoptotic rate, attenuated oxidative stress and improved mitochondrial membrane potential in N2a/Swe." | 5.38 | Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. ( Gong, K; Gong, Y; Ma, T; Tang, P; Yan, Y; Zhang, L; Zhang, X; Zhao, N, 2012) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| " These activities, associated to a good predictive bioavailability and a lack of cytotoxicity, design it as a promising hit for further in vivo investigation." | 1.43 | Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. ( Corvaisier, S; Cresteil, T; Dallemagne, P; El Kihel, L; Jourdan, JP; Lecoutey, C; Legay, R; Malzert-Fréon, A; Rochais, C; Since, M; Sopkova-de Oliveira Santos, J, 2016) |
| "Edaravone is a potent free radical scavenger that exerts antioxidant effects." | 1.42 | Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease. ( Li, F; Li, J; Liu, X; Wang, Q; Yang, R, 2015) |
| "Treatment with edaravone significantly improved STZ-induced cognitive damage as evaluated in Morris water maze and step-down tests and markedly restored changes in malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) adducts, hydroxyl radical (OH), hydrogen peroxide (H2O2), total superoxide dismutase (T-SOD), reduced glutathione (GSH), glutathione peroxidase (GPx) and protein carbonyl (PC) levels." | 1.39 | Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. ( Chi, L; Yu, G; Zhang, L; Zhang, W; Zhang, Y; Zhou, S; Zhu, J, 2013) |
| "Edaravone is a novel free radical scavenger currently used to reduce cerebral damages after acute cerebral infarction." | 1.39 | Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells. ( Liu, C; Shen, YE; Wang, Y; Yu, GC; Zhang, LM; Zhang, ZY, 2013) |
| "Edaravone treatment significantly elevated cell viability, reduced apoptotic rate, attenuated oxidative stress and improved mitochondrial membrane potential in N2a/Swe." | 1.38 | Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. ( Gong, K; Gong, Y; Ma, T; Tang, P; Yan, Y; Zhang, L; Zhang, X; Zhao, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jourdan, JP | 1 |
| Since, M | 1 |
| El Kihel, L | 1 |
| Lecoutey, C | 1 |
| Corvaisier, S | 1 |
| Legay, R | 1 |
| Sopkova-de Oliveira Santos, J | 1 |
| Cresteil, T | 1 |
| Malzert-Fréon, A | 1 |
| Rochais, C | 1 |
| Dallemagne, P | 1 |
| Zhou, S | 1 |
| Yu, G | 1 |
| Chi, L | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Zhang, Y | 1 |
| Zhang, L | 2 |
| He, F | 1 |
| Cao, YP | 1 |
| Che, FY | 1 |
| Yang, LH | 1 |
| Xiao, SH | 1 |
| Liu, J | 2 |
| Jiao, SS | 1 |
| Yao, XQ | 1 |
| Liu, YH | 1 |
| Wang, QH | 1 |
| Zeng, F | 1 |
| Lu, JJ | 1 |
| Zhu, C | 1 |
| Shen, LL | 1 |
| Liu, CH | 1 |
| Wang, YR | 1 |
| Zeng, GH | 1 |
| Parikh, A | 1 |
| Chen, J | 1 |
| Liang, CR | 1 |
| Xiang, Y | 1 |
| Bu, XL | 1 |
| Deng, J | 1 |
| Li, J | 2 |
| Xu, J | 1 |
| Zeng, YQ | 1 |
| Xu, X | 1 |
| Xu, HW | 1 |
| Zhong, JH | 1 |
| Zhou, HD | 1 |
| Zhou, XF | 1 |
| Wang, YJ | 1 |
| Yang, R | 1 |
| Wang, Q | 1 |
| Li, F | 1 |
| Liu, X | 1 |
| Qiang, X | 1 |
| Li, Y | 1 |
| Yang, X | 1 |
| Luo, L | 1 |
| Xu, R | 1 |
| Zheng, Y | 1 |
| Cao, Z | 1 |
| Tan, Z | 1 |
| Deng, Y | 1 |
| Yan, Y | 1 |
| Gong, K | 1 |
| Ma, T | 1 |
| Zhao, N | 1 |
| Zhang, X | 1 |
| Tang, P | 1 |
| Gong, Y | 1 |
| Shen, YE | 1 |
| Wang, Y | 1 |
| Yu, GC | 1 |
| Liu, C | 1 |
| Zhang, ZY | 1 |
| Zhang, LM | 1 |
| Nihashi, T | 1 |
| Yatsuya, H | 1 |
| Hayasaka, K | 1 |
| Kato, R | 1 |
| Kawatsu, S | 1 |
| Arahata, Y | 1 |
| Iwai, K | 1 |
| Takeda, A | 1 |
| Washimi, Y | 1 |
| Yoshimura, K | 1 |
| Mizuno, K | 1 |
| Kato, T | 1 |
| Naganawa, S | 1 |
| Ito, K | 1 |
| Takagi, A | 1 |
| Ishihara, S | 1 |
| Kondo, T | 1 |
| Sakakibara, H | 1 |
| Toyoshima, H | 1 |
| Kono, K | 1 |
| Iguchi, A | 1 |
| Yoshida, F | 1 |
| Miyao, M | 1 |
10 other studies available for antipyrine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzyl Compounds; Cell Proliferation; Dose-R | 2016 |
Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats.
Topics: Alzheimer Disease; Animals; Antipyrine; Cognition Disorders; Edaravone; Free Radical Scavengers; Inf | 2013 |
Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; CA1 Region, Hippocampal; Disease Mode | 2014 |
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.
Topics: Administration, Oral; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Antipyrine; Behavi | 2015 |
Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease.
Topics: Acetylcholinesterase; Aldehydes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipyrine; Chol | 2015 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells.
Topics: Alzheimer Disease; Animals; Antipyrine; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Surviva | 2012 |
Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antipyrine; Cell Line, Tumor; Cell Survival; Dose | 2013 |
Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients.
Topics: Alzheimer Disease; Antipyrine; Glucose-6-Phosphate; Humans; Imaging, Three-Dimensional; Positron-Emi | 2007 |
Age effects on pupil dilation among Alzheimer's patients.
Topics: Acetaminophen; Aged; Aged, 80 and over; Alzheimer Disease; Antipyrine; Chloral Hydrate; Drug Combina | 1999 |